Jonathan Alspaugh, Chief Financial Officer at Aeglea BioTherapeutics, Inc. (AGLE), bought 50,152 shares at $6.50 ($325K) on 2021-08-17, disclosed to the SEC on 2021-08-18.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $6.37 | 9,780 | $62K | 19.2% |
| 2 | $6.37 | 9,780 | $62K | 19.2% |
| 3 | $6.50 | 23,392 | $152K | 46.8% |
| 4 | $6.72 | 7,200 | $48K | 14.9% |
| Total | $6.48 avg | 50,152 | $325K | 100% |
| Filing → |